HC Wainwright Comments on Shattuck Labs Q1 Earnings

Shattuck Labs, Inc. (NASDAQ:STTK) – Analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Shattuck Labs in a note issued to investors on Thursday, March 5th. HC Wainwright analyst J. Pantginis expects that the company will post earnings per share of ($0.18) for the quarter. HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Shattuck Labs’ current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Shattuck Labs’ Q2 2026 earnings at ($0.19) EPS, Q3 2026 earnings at ($0.22) EPS, Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($0.83) EPS, FY2027 earnings at ($0.88) EPS and FY2028 earnings at ($1.04) EPS.

Shattuck Labs (NASDAQ:STTK) last posted its earnings results on Thursday, March 5th. The company reported ($0.12) EPS for the quarter, hitting analysts’ consensus estimates of ($0.12). The firm had revenue of ($1.00) million during the quarter, compared to analysts’ expectations of $0.17 million.

Several other analysts have also recently issued reports on STTK. Needham & Company LLC assumed coverage on Shattuck Labs in a report on Friday. They set a “buy” rating and a $25.00 price objective on the stock. Wedbush boosted their price target on shares of Shattuck Labs from $4.00 to $8.00 and gave the stock an “outperform” rating in a research report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Shattuck Labs in a research note on Thursday, January 22nd. Citigroup increased their price objective on shares of Shattuck Labs from $2.00 to $4.00 and gave the company a “neutral” rating in a research report on Tuesday, January 6th. Finally, TD Cowen reissued a “buy” rating on shares of Shattuck Labs in a research note on Friday. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $10.00.

Shattuck Labs Price Performance

NASDAQ STTK opened at $5.99 on Monday. Shattuck Labs has a 1-year low of $0.69 and a 1-year high of $6.00. The business has a 50 day simple moving average of $4.17 and a two-hundred day simple moving average of $2.85. The stock has a market capitalization of $379.05 million, a PE ratio of -7.78 and a beta of 1.55.

Hedge Funds Weigh In On Shattuck Labs

A number of large investors have recently made changes to their positions in STTK. Turtle Creek Wealth Advisors LLC bought a new position in Shattuck Labs during the 3rd quarter valued at about $29,000. Virtu Financial LLC purchased a new position in shares of Shattuck Labs during the third quarter valued at approximately $38,000. Squarepoint Ops LLC bought a new position in shares of Shattuck Labs during the third quarter valued at approximately $46,000. Mallini Complete Financial Planning LLC bought a new position in shares of Shattuck Labs during the fourth quarter valued at approximately $83,000. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of Shattuck Labs in the fourth quarter worth approximately $85,000. 58.74% of the stock is owned by hedge funds and other institutional investors.

Shattuck Labs Company Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.